Investigation reveals added value of APT MRI in detecting clinically significant prostate cancer, suggesting improved diagnostic performance over PI-RADS alone.
Motivation: It has been reported amide proton transfer (APT) weighted MRI can differentiate clinically significant prostate cancer (csPCa), but its added value to PI-RADS remains uncertain. Goal(s): Investigating if APT weighted MRI can provide added value to PI-RADS v2.1 in diagnosing csPCa. Approach: 134 participants were enrolled. They were additionally imaged with APT weighted MRI before pathological examination. APT and apparent diffusion coefficient (ADC) values of lesion were analyzed. Results: APT, ADC, and PI-RADS can significantly differentiate csPCa from non-csPCa. Compared with using PI-RADS alone, the combination of APT and PI-RADS can significantly improve the diagnostic performance. Impact: Accurately diagnosing csPCa patients is important for treatment selection. APT weighted MRI can provide significantly added value to PI-RADS v2.1 for identifying csPCa. Therefore, the application of APT weighted MRI would be beneficial for prostate cancer assessment and management.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: